A PHP Error was encountered

Severity: Warning

Message: fopen(/var/cpanel/php/sessions/ea-php80/ci_session6fa727afae62e403f98a51e968b0b4e7745c2beb): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 174

Backtrace:

File: /home/judfadzm/public_html/webinar4demand.com/application/controllers/News.php
Line: 23
Function: library

File: /home/judfadzm/public_html/webinar4demand.com/index.php
Line: 317
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/cpanel/php/sessions/ea-php80)

Filename: Session/Session.php

Line Number: 143

Backtrace:

File: /home/judfadzm/public_html/webinar4demand.com/application/controllers/News.php
Line: 23
Function: library

File: /home/judfadzm/public_html/webinar4demand.com/index.php
Line: 317
Function: require_once

Veracyte to Participate in Upcoming Investor Conferences

Loading...

Veracyte to Participate in Upcoming Investor Conferences

Veracyte to Participate in Upcoming Investor Conferences

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413

Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in th e following investor conferences.

  • Raymond James 46th Annual Institutional Investors Conference – Orlando, FL
    Presentation on March 5th at 9:50 a.m. Eastern Time
  • Leerink Partners Global Healthcare Conference – Miami, FL
    Fireside Chat on March 11th at 8:40 a.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).


Visitor Count 35657